The previous study also suggested that drugs either reducing amyloid, preventing tau hyperphosphorylation, or modifying neurodegeneration were reliable for earlier intervention through feasible methods for early detection of preclinical AD [13]. The gene discussed is MAPT; the disease is Alzheimer disease.